Return
Human iPSC-derived engineered heart tissue model of diastolic dysfunction in heart failure with preserved ejection fraction
H
K
T
U
S
D
Y
K
M
M
T
Y
Y
Y
M
K
A
M
S
DOI:10.1016/j.stem.2026.06.007.png)
Abstract
En 中文
• hiPSC-derived engineered heart tissues recapitulate key features of HFpEF • SGLT2i ameliorates the HFpEF-like phenotype via anti-inflammatory effects • Restoration of endothelial eNOS-NO-cGMP-PKG signaling mediates SGLT2i effects
Keywords:
heart failure with preserved ejection fraction
HFpEF
human induced pluripotent stem cells
engineered heart tissue
sodium-glucose cotransporter 2 inhibitor
SGLT2i
drug discovery
diastolic dysfunction
eNOS-NO-cGMP-PKG signaling pathway
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
20.4
Papers:
3.6K
Citations:
3.1W
